Expression Of RN181 And P-ERK In Invasive Ductal Carcinoma Of The Breast And Its Clinicopathological Significance

ObjectiveRing finger protein 181(RNF181,RN181),also known as HSPC238,is a member of the ring finger protein superfamily and has a RING domain and E3 ubiquitin linking enzyme activity.In many tumors such as hepatocellular carcinoma and diffuse large B-cell lymphoma,RN181 can regulate the progression of tumors through MAPK/ERK signaling pathway or ubiquitination pathway,respectively.Breast cancer is the most common malignant tumor in women[1,2].Infiltrating ductal carcinoma is the most common pathological type.The expression of RN181 in invasive ductal carcinoma of the breast and its relationship with P-ERK is irrelevant.The purpose of this study was to investigate the expression of RN181 in invasive ductal carcinoma of the breast and its relationship with clinicopathological parameters,and its correlation with the expression of P-ERK protein in breast invasive ductal carcinoma,To preliminarily reveal the role of RN181 in the occurrence and development of invasive ductal carcinoma of the breast and its clinical diagnostic significance for invasive ductal carcinoma of the breast.MethodsPostoperative follow-up data of breast cancer in GEO database were statistically analyzed.The survival curve was drawn by Kaplan-Meier method.The effect of RN181 expression on the survival time of breast invasive ductal carcinoma was analyzed.by Log-Rank test and verification by immunohistochemistry Seventy Nine cases of female breast infiltrating ductal carcinoma wereselected and diagnosed by pathology from January 2015 to December 2015 as experimental group,including luminal type A(ER+ and/or PR+ and HER-2-)28 cases,luminal type B(ER+ and There were 30 cases of/or PR+ and HER-2+),10 cases of HER2 over-expression(ER-,PR-,and HER-2+),and 11 cases of triple-negative(ER-,PR-,and HER-2-).Thirty-six normal adjacent tissues were selected as controls.The immunohistochemistry technique Envision was used to detect the expression of RN181 and P-ERK in 79 cases of breast invasive ductal carcinoma and 36 cases of adjacent tissues.In addition,the relationship between the expression of RN181 and the clinicopathological features of breast invasive ductal carcinoma patients,and the correlation between RN181 and P-ERK proteins were analyzed.Results1.In the GEO database,the survival curve of breast cancer patients showed that the survival rate of patients with low expression of RN181 in cancer tissues was significantly lower than that of breast cancer patients with high expression of RN1812.The results of immunohistochemical staining showed that the expression of RN181 in seventy nine cases of breast invasive ductal carcinoma was significantly lower than that in the control group(p<0.01).The expression of RN181 was significantly lower in cases with lymph node metastasis than in cases with no lymph node metastasis(p<0.01).However,there was no statistically significant difference in the expression of RN181 and the patient's age,tumor size,and histological grade(p>0.05).3.RN181 is differentially expressed in different molecular subtypes of breast cancer.The expression of RH181 in Luminal B type breast cancer is significantly lower than that in the other three subtypes(Luminal A,Her-2 overexpression,and triple negative)(p<0.01).4.The expression of P-ERK in breast invasive ductal carcinoma was positively correlated with the size of the tumor(p<0.01,),and positively correlated with the histological grade of the tumor(p<0.05),but not with age and lymph node metastasis(p>0.05).5.There was no correlation between the expression of RN181 and P-ERK in breast invasive ductal carcinoma(p>0.05,r=-0.05).Conclusions1.RN181 is lowly expressed in invasive ductal carcinoma of the breast,with high expression in adjacent tissues and negatively correlated with lymph node metastases.Analysis of the survival curve of breast cancer patients in the GEO database showed that RN181 was lowly expressed in cancer tissues.The survival rate of patients was significantly lower than that of breast cancer patients with high RN181 expression.The above suggested that RN181 may be involved in the regulation of breast cancer as a new tumor suppressor factor.2.RN181 showed low specificity in LuminalB type breast cancer,suggesting that RN181 may be a new indicator to evaluate breast cancer molecular typing and guide individualized treatment of breast cancer.3.The expression of 3.P-ERK in breast invasive ductal carcinoma was positively correlated with tumor size and histological grade,while RN181 was not correlated with the expression of P-ERK protein.